News
April 2, 2024
EQT Acquires Melkonian Capital Management Portfolio Company Avetta in $3 Billion Deal
September 16, 2020
Santen Acquires Melkonian Capital Management Portfolio Company Eyevance for $225 Million
February 14, 2019
Melkonian Capital Management Portfolio Company BROWZ Merges With Avetta
May 1, 2018
Melkonian Capital Management Portfolio Company Sebela Pharmaceuticals Acquires Braintree Labs
March 19, 2014
Horizon Pharma Acquires Melkonian Capital Management Portfolio Company Vidara in $660 Million Deal
August 30, 2010
MEDA Acquires Melkonian Capital Management Portfolio Company Alaven Pharmaceutical For $350 Million
The materials presented herein are being provided for information purposes only to provide an overview of certain Melkonian Capital Management’s (“MCM”) past investments and do not constitute an offer to sell or a solicitation of an offer to buy any interest in any MCM managed product or any of its holdings. Before you decide to invest or maintain an investment in any MCM managed product, you should carefully read the product’s offering documents to determine whether an investment is suitable for you in light of your circumstances, investment objectives, financial situation and risk tolerance. The materials presented herein include past private investments made by MCM that have been material to the investment portfolio. The materials do not include all of the securities purchased, sold, or recommended by MCM. The materials should not be the basis of any investment decision. Success of any past investment is not indicative of future results. It should not be assumed that any future investment by MCM will be profitable. There is no assurance that similar investment opportunities will be suitable or available to MCM in the future. An investment in an MCM managed product entails certain risks, including the possible loss of the entire principal amount invested. For further important disclosures integral to these materials please see Terms of Use and Disclaimers.